摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-tert-butyl-1-(4-(2-morpholinoethoxy) phenyl)-1H-pyrazol-5-amine | 1241507-55-0

中文名称
——
中文别名
——
英文名称
3-tert-butyl-1-(4-(2-morpholinoethoxy) phenyl)-1H-pyrazol-5-amine
英文别名
5-tert-Butyl-2-[4-(2-morpholin-4-yl-ethoxy)-phenyl]-2H-pyrazol-3-ylamine;5-tert-butyl-2-[4-(2-morpholin-4-ylethoxy)phenyl]pyrazol-3-amine
3-tert-butyl-1-(4-(2-morpholinoethoxy) phenyl)-1H-pyrazol-5-amine化学式
CAS
1241507-55-0
化学式
C19H28N4O2
mdl
——
分子量
344.457
InChiKey
HYHCZLRJKXSDSU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    25
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.53
  • 拓扑面积:
    65.5
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] PYRIDYLUREA DERIVATIVES AND THEIR THERAPEUTIC USE<br/>[FR] DÉRIVÉS DE PYRIDYLURÉE ET LEUR UTILISATION THÉRAPEUTIQUE
    申请人:PULMAGEN THERAPEUTICS INFLAMMA
    公开号:WO2010131030A1
    公开(公告)日:2010-11-18
    Compounds of formula (IA) are inhibitors of p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract formula (IA). wherein R 1 is a radical of formula (IIA), (IIB), or (IIC); wherein m is 0 or 1; T is N or CH; R 2a, R 2b, R 2c are independently selected from H, halogen and C1 -C6 alkyl; R3 is H or F; R4 is -CH3; -C2 H5; -CH2OH, CH2SCH3; - SCH3 or -SC2H5; R5 is -CH3 or -C2H5; R6 is H, or represents one or more 10 substituents, each independently selected from C1 -C6 alkyl, hydroxy, halogen, and radicals of formulae (IIIA), (IIIB) and (IIIC):IA)(IIIB)(IIIC); wherein R61a and R61b are independently H or C1-C6 alkyl, or R61a and R61b taken together with the nitrogen to which they are attached to form a 6-membered 15 heterocyclic ring optionally containing a further heteroatom selected from N and O; n is 0, 1 or 2; p is 1 or 2; R7 is H or F; and R8 is H or CONH2.
    式(IA)的化合物是p38 MAPK抑制剂,可用作抗炎药物,用于治疗呼吸道疾病等疾病。其中R1是式(IIA)、(IIB)或(IIC)的基团;m为0或1;T为N或CH;R2a、R2b、R2c分别选自H、卤素和C1-C6烷基;R3为H或F;R4为-CH3;-C2 H5;-CH2OH、CH2SCH3;-SCH3或-SC2H5;R5为-CH3或-C2H5;R6为H,或表示一个或多个取自C1-C6烷基、羟基、卤素和式(IIIA)、(IIIB)和(IIIC)的基团的取代基,其中R61a和R61b分别独立为H或C1-C6烷基,或R61a和R61b一起与它们连接的氮原子形成一个6元杂环环,可选地含有进一步选择自N和O的异原子;n为0、1或2;p为1或2;R7为H或F;R8为H或CONH2。
  • [EN] PYRAZOLE DERIVATIVES AS P38 MAP INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLE UTILISÉS COMME INHIBITEURS DE MAP P38
    申请人:RESPIVERT LIMTED
    公开号:WO2014033448A1
    公开(公告)日:2014-03-06
    Compounds of formula (I) wherein R1, R2, J, Q, V, X, Y and Z are defined herein are disclosed. The compounds are inhibitors of the family of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha sub-type thereof, and of Syk kinase and the Src family of tyrosine kinases. The compounds may be used in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, in particular inflammatory diseases of the lung, such as asthma and COPD, as well as those of the gastrointestinal tract, such as ulcerative colitis and Crohn's disease and of the eye, such as uveitis.
    公开了具有式(I)的化合物,其中R1、R2、J、Q、V、X、Y和Z的定义如本文所述。这些化合物是p38丝裂原活化蛋白激酶酶家族(以下简称为p38 MAP激酶抑制剂)的抑制剂,特别是其α亚型,以及Syk激酶和Src酪氨酸激酶家族的抑制剂。这些化合物可用于治疗,包括在药物组合中,特别是用于治疗炎症性疾病,特别是肺部的炎症性疾病,如哮喘和COPD,以及胃肠道的炎症性疾病,如溃疡性结肠炎和克罗恩病,以及眼部的炎症性疾病,如葡萄膜炎。
  • [EN] TRIAZOLOPYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE TRIAZOLOPYRIDINE UTILISÉS COMME INHIBITEURS DE LA P38 MAP KINASE
    申请人:PULMAGEN THERAPEUTICS INFLAMMA
    公开号:WO2010094956A1
    公开(公告)日:2010-08-26
    Compounds of formula (I) are inhibitors of p38 MAP kinase, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract wherein; R1 is C1-C6 alkyl, C3-C6 cycloalkyl, phenyl which is optionally substituted, 5- or 6 membered monocyclic heteroaryl which is optionally substituted, or a radical of formula (II) wherein n is 1 or 2, and R3 and R4 are independently H or C1-C6 alkyl, or R3 and R4 taken together with the nitrogen to which they are attached form a 6- membered heterocyclic ring optionally containing a further heteroatom selected from N and O; Y is -O- or -S(O)P- wherein p is 0, 1 or 2; A is an optionally substituted divalent arylene radical, or a mono- or bicyclic heteroarylene radical, or a C3-C6 divale nt cycloalkylene radical having 5 or 6 ring atoms, or a piperidinylene radical wherein the ring nitrogen is linked to R2NHC(=O)W-; W is a bond, -NH- or -C(RA)(RB), wherein RA and RB are independently H, methyl, ethyl, amino, hydroxyl or halo; and R2 is a radical as defined in the claims.
    化合物的结构式(I)是p38 MAP激酶的抑制剂,在治疗呼吸道疾病等疾病中作为抗炎药物有用;其中,R1是C1-C6烷基,C3-C6环烷基,苯基(可选择性取代),5-或6-成员单环杂芳基(可选择性取代),或者是结构式(II)中的基团,其中n为1或2,R3和R4独立地是H或C1-C6烷基,或者R3和R4与它们连接的氮一起形成一个6-成员杂环环,可选择性地含有进一步从N和O中选择的杂原子;Y是-O-或-S(O)P-,其中p为0、1或2;A是一个可选择性取代的二价芳基基团,或者是一个单环或双环杂芳基基团,或者是一个具有5或6个环原子的C3-C6二价环烷基基团,或者是一个哌啶基团,其中环氮与R2NHC(=O)W-连接;W是一个键,-NH-或-C(RA)(RB),其中RA和RB独立地是H、甲基、乙基、氨基、羟基或卤素;而R2是如权利要求中定义的基团。
  • TRIAZOLOPYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USE
    申请人:Finch Harry
    公开号:US20120088763A1
    公开(公告)日:2012-04-12
    Compounds of formula (I) are inhibitors of p38 MAP kinase, useful as anti-inflammatory agents in the treatment of inter alia, diseases of the respiratory tract wherein; R 1 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, phenyl which is optionally substituted, 5- or 6 membered monocyclic heteroaryl which is optionally substituted, or a radical of formula (II) wherein n is 1 or 2, and R 3 and R 4 are independently H or C 1 -C 6 alkyl, or R 3 and R 4 taken together with the nitrogen to which they are attached form a 6-membered heterocyclic ring optionally containing a further heteroatom selected from N and O; Y is —O— or —S(O) p — wherein p is 0, 1 or 2; A is an optionally substituted divalent arylene radical, or a mono- or bicyclic heteroarylene radical, or a C 3 -C 6 divalent cycloalkylene radical having 5 or 6 ring atoms, or a piperidinylene radical wherein the ring nitrogen is linked to R 2 NHC(═O)W—; W is a bond, —NH— or —C(R A )(R B ), wherein R A and R B are independently H, methyl, ethyl, amino, hydroxyl or halo; and R 2 is a radical as defined in the claims.
    化合物(I)的式子是抑制p38 MAP激酶的,可用于治疗呼吸道疾病等炎症疾病,其中:R1为C1-C6烷基,C3-C6环烷基,苯基(可选取代基),5-或6-成员单环杂芳基(可选取代基),或式子(II)中的基团,其中n为1或2,R3和R4独立地为H或C1-C6烷基,或R3和R4与它们连接的氮一起形成一个6-成员杂环环,该环可选地包含进一步的杂原子,所选自N和O;Y为—O—或—S(O)p—,其中p为0,1或2;A为可选取代的二价芳基基团,或单环或双环杂芳基基团,或具有5个或6个环原子的C3-C6二价环烷基基团,或哌啶基团,其中环氮连接到R2NHC(═O)W—;W为键,—NH—或—C(RA)(RB),其中RA和RB独立地为H,甲基,乙基,氨基,羟基或卤素;而R2则为声明中所定义的基团。
  • Triazolopyridine derivatives and their therapeutic use
    申请人:Finch Harry
    公开号:US08557797B2
    公开(公告)日:2013-10-15
    Compounds of formula (I) are inhibitors of p38 MAP kinase, useful as anti-inflammatory agents in the treatment of inter alia, diseases of the respiratory tract wherein; R1 is C1-C6 alkyl, C3-C6 cycloalkyl, phenyl which is optionally substituted, 5- or 6 membered monocyclic heteroaryl which is optionally substituted, or a radical of formula (II) wherein n is 1 or 2, and R3 and R4 are independently H or C1-C6 alkyl, or R3 and R4 taken together with the nitrogen to which they are attached form a 6-membered heterocyclic ring optionally containing a further heteroatom selected from N and O; Y is —O— or —S(O)p— wherein p is 0, 1 or 2; A is an optionally substituted divalent arylene radical, or a mono- or bicyclic heteroarylene radical, or a C3-C6 divalent cycloalkylene radical having 5 or 6 ring atoms, or a piperidinylene radical wherein the ring nitrogen is linked to R2NHC(═O)W—; W is a bond, —NH— or —C(RA)(RB), wherein RA and RB are independently H, methyl, ethyl, amino, hydroxyl or halo; and R2 is a radical as defined in the claims.
    式(I)的化合物是p38 MAP激酶的抑制剂,在治疗呼吸道疾病等疾病中作为抗炎剂有用;其中,R1为C1-C6烷基,C3-C6环烷基,苯基(可选择性取代),5-或6-成员的单环杂芳基(可选择性取代),或式(II)中的基团,其中n为1或2,R3和R4分别独立地为H或C1-C6烷基,或R3和R4与它们所连接的氮一起形成一个6-成员的杂环,该杂环可选择性地含有进一步从N和O中选择的杂原子;Y为—O—或—S(O)p—,其中p为0,1或2;A为可选择性取代的二价芳基基团,或单环或双环杂芳基基团,或具有5或6个环原子的C3-C6二价环烷基基团,或一种哌啶基团,其中环氮与R2NHC(═O)W—连接;W为键,—NH—或—C(RA)(RB),其中RA和RB分别独立地为H,甲基,乙基,氨基,羟基或卤素;R2为声明中定义的基团。
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺